Hypothesis

BPC-157 reverses age‑associated gut‑brain dysfunction by directly targeting senescent microbes and their secretory phenotype, thereby restoring vagal‑mediated serotonergic balance and dampening inflammaging.

Mechanistic Rationale

Aging is marked by enteric hyperserotonemia, central serotonergic depletion, increased intestinal permeability, and a shift toward a pro‑inflammatory microbiome. BPC-157 already shows opposing effects on serotonin synthesis—reducing release in the gut while boosting hippocampal and nigrostriatal production—and activates VEGFR2‑Akt‑eNOS, FAK‑paxillin, and JAK‑2 pathways that promote barrier repair and glial survival. What is missing is a link between these actions and the microbial community.

We propose that BPC-157 acts as a peptide senomodulator: it selectively interferes with the metabolic state of senescent bacteria, curbing their senescence‑associated secretory phenotype (mSASP). Senescent microbes release amplified LPS, peptidoglycan fragments, and metabolites that drive TLR4‑NF‑κB signaling in epithelial and immune cells, perpetuating barrier leak and systemic inflammation. By dampening mSASP, BPC-157 would lower luminal endotoxin load, tighten junctions via VEGFR2‑Akt‑eNOS signaling, and reduce vagal afferent firing of inflammatory cues. Consequently, central serotonergic neurons would receive less inhibitory cytokine input, allowing the peptide’s pro‑serotonergic action in the hippocampus to manifest.

This integrates three layers: (1) direct antimicrobial/senescence‑shifting activity of BPC-157 on the microbiota, (2) downstream restoration of gut barrier and vagal signaling, and (3) re‑balancing of brain serotonin systems via reduced inflammatory tone.

Testable Predictions

1. Microbiota shift – 16S rRNA sequencing of aged mice treated with BPC-157 will show reduced abundance of taxa linked to microbial senescence (e.g., increased Bacteroides vulgatus, decreased Akkermansia muciniphila) and a metagenomic signature of lower mSASP genes (e.g., decreased lsr quorum‑sensing, reduced csgA amyloid curli).
2. Barrier integrity – Oral FITC‑dextran assay will demonstrate decreased permeability in BPC-157‑treated old mice compared with vehicle controls.
3. Systemic inflammation – Plasma IL‑6, TNF‑α, and LPS‑binding protein will be significantly lower after chronic BPC-157 administration.
4. Vagal tone – Heart‑rate variability indices (RMSSD) will increase, indicating restored vagal afferent signaling.
5. Brain serotonin & behavior – Hippocampal serotonin levels (HPLC) will rise, correlating with improved performance in the Morris water maze and reduced depressive‑like behavior in the sucrose preference test.
6. Falsifiability – If BPC-157 fails to alter microbial senescence markers or barrier function despite central serotonergic changes, the proposed microbial senomodulation mechanism is refuted.

Experimental Design (Aged C57BL/6 mice, 24‑mo)

• Groups: (i) Vehicle, (ii) BPC-157 10 µg/kg/day subcutaneously for 8 weeks, (iii) BPC-157 + vagotomy (to test vagal dependence).
• Readouts collected at baseline, week 4, week 8: microbiota composition, metagenomics for senescence pathways, FITC‑dextran permeability, plasma cytokines, vagal electrophysiology, hippocampal serotonin, behavioral assays.

Novel Insight

Beyond its known angiogenic and trophic effects, BPC-157 may function as a peptide‑based senolytic for the microbiome, directly curbing the inflammaging signal at its source. This reframes the gut‑brain axis not merely as a conduit of host‑derived signals but as a interface where microbial aging drives host aging—a targetable node that BPC-157 uniquely engages.